XML 21 R4.htm IDEA: XBRL DOCUMENT v3.25.3
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Operating expenses:        
Research and development $ 5,039 $ 7,208 $ 19,823 $ 22,947
General and administrative 3,006 3,136 9,049 8,563
Total operating expenses 8,045 10,344 28,872 31,510
Loss from operations (8,045) (10,344) (28,872) (31,510)
Other (expense) income        
Change in fair value of warrant liabilities (1,811) (5,617) (3,177) (3,279)
Loss on issuance of pre-funded warrants 0 (2,924) 0 (3,502)
Gain on sale of equipment 0 0 0 3
Foreign exchange transaction (loss) gain 0 (1) 0 143
Grant income 0 0 415 0
Interest income 199 185 577 472
Interest expense (426) (137) (796) (221)
Total other (expense), net (2,038) (8,494) (2,981) (6,384)
Net loss (10,083) (18,838) (31,853) (37,894)
Other comprehensive income (loss):        
Foreign currency translation adjustment 39 36 144 (5)
Comprehensive loss $ (10,044) $ (18,802) $ (31,709) $ (37,899)
Net loss per common share, basic (in dollars per share) $ (0.60) $ (1.39) $ (2.09) $ (3.23)
Net loss per common share, diluted (in dollars per share) $ (0.60) $ (1.39) $ (2.09) $ (3.23)
Weighted average common shares and pre-funded warrants outstanding, basic (in shares) 16,692,476 13,582,345 15,247,864 11,720,527
Weighted average common shares and pre-funded warrants outstanding, diluted (in shares) 16,692,476 13,582,345 15,247,864 11,720,527